# A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC

> clinical trial · VERIFIED · 2026-06-04

Status: RECRUITING · Sponsor: Shanghai Henlius Biotech · Condition: Non Small Cell Lung Cancer

- Company: Shanghai Henlius Biotech
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07269782

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED.